Kwiatkowska Katarzyna Malgorzata, Garagnani Paolo, Bonafé Massimiliano, Bacalini Maria G, Sala Claudia, Castellani Gastone, Gentilini Davide, Calzari Luciano, Ziegler Dan, Gerrits Monique M, Faber Catharina G, Malik Rayaz A, Marchi Margherita, Salvi Erika, Lauria Giuseppe, Pirazzini Chiara
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Diabetes. 2025 Apr 1;74(4):640-650. doi: 10.2337/db24-0930.
Approximately one out of two patients with diabetes develops diabetic neuropathy; of these, 20% experience neuropathic pain. Risk factors for neuropathic pain are largely unknown; however, DNA methylation was recently associated with neuropathies and degeneration of nerve fibers. The aim of this work was to describe the DNA methylation signature and identify genes associated with neuropathic pain in type 2 diabetes mellitus (T2DM). We discovered distinct DNA methylation signatures that differentiate painful and painless neuropathy phenotypes associated with T2DM and identified genes with potential as therapeutic targets for neuropathic pain, such as GCH1, MYT1L, and MED16. This work can serve as reference hallmark for future studies on painful diabetic neuropathy and other chronic pain conditions.
大约每两名糖尿病患者中就有一人会发展为糖尿病神经病变；其中，20%会经历神经性疼痛。神经性疼痛的风险因素在很大程度上尚不清楚；然而，DNA甲基化最近与神经病变和神经纤维退化有关。这项工作的目的是描述DNA甲基化特征，并识别与2型糖尿病（T2DM）神经性疼痛相关的基因。我们发现了不同的DNA甲基化特征，这些特征区分了与T2DM相关的疼痛性和无痛性神经病变表型，并确定了具有作为神经性疼痛治疗靶点潜力的基因，如GCH1、MYT1L和MED16。这项工作可以作为未来关于疼痛性糖尿病神经病变和其他慢性疼痛病症研究的参考标志。
